• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2011 - Product Image

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2011

  • ID: 1964195
  • November 2011
  • 50 pages
  • Global Markets Direct

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2011', provides an overview of the Allergic Rhino-Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis.
- A review of the Allergic READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Allergic Rhino-Conjunctivitis Overview
Therapeutics Development
An Overview of Pipeline Products for Allergic Rhino-Conjunctivitis
Allergic Rhino-Conjunctivitis Therapeutics under Development by Companies
Allergic Rhino-Conjunctivitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Allergic Rhino-Conjunctivitis Therapeutics - Products under Development by Companies
Allergic Rhino-Conjunctivitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Allergic Rhino-Conjunctivitis Therapeutics Development
Merck & Co., Inc.
ALK-Abello A/S
Merck KGaA
Stallergenes S.A.
Cytos Biotechnology AG
Allergopharma Joachim Ganzer KG
Oxagen Limited
Laboratorios LETI S.L.
Allergic Rhino-Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CYT003-QbG10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen Extract Of Phleum Pratense - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-7243 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olea Europaea Pollen Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Modified Allergen Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0704rP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mutaflor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALK Ragweed Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0206st - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Depigoid Birch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gpASIT + TM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0701rP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osiris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clustoid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OC002417 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergic Rhino-Conjunctivitis Therapeutics – Drug Profile Updates
Allergic Rhino-Conjunctivitis - Featured News
May 24, 2011: Paladin Labs Files New Drug Submission For Oralair
Apr 18, 2011: ALK To Receive GRAZAX Reimbursement In Denmark
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Allergic Rhino-Conjunctivitis, H2 2011
Products under Development for Allergic Rhino-Conjunctivitis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Merck & Co., Inc., H2 2011
ALK-Abello A/S, H2 2011
Merck KGaA, H2 2011
Stallergenes S.A., H2 2011
Cytos Biotechnology AG, H2 2011
Allergopharma Joachim Ganzer KG, H2 2011
Oxagen Limited, H2 2011
Laboratorios LETI S.L., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Allergic Rhino-Conjunctivitis Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2011
Products under Development for Allergic Rhino-Conjunctivitis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos